

Overview

Useful For

Evaluating patients with a personal or family history suggestive of a hereditary renal cancer syndrome

Establishing a diagnosis of a hereditary renal cancer syndrome allowing for targeted cancer surveillance based on associated risks

Identifying genetic variants associated with increased risk for renal and/or other cancers, allowing for predictive testing and appropriate screening of at-risk family members

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 19 genes associated with hereditary renal cancer syndromes: *BAP1*, *DICER1*, *FH*, *FLCN*, *MET*, *MITF* (c.952G>A p.E318K variant only), *PTEN* (including promoter), *SDHA*, *SDHAF2*, *SDHB*, *SDHC*, *SDHD*, *SMARCA4*, *SMARCB1*, *TMEM127*, *TP53*, *TSC1*, *TSC2*, and *VHL*. See [Targeted Genes and Methodology Details for Hereditary Renal Cancer Panel](#) and Method Description for additional details.

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for hereditary renal cancer.

Special Instructions

- [Molecular Genetics: Inherited Cancer Syndromes Patient Information](#)
- [Informed Consent for Genetic Testing](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Targeted Genes and Methodology Details for Hereditary Renal Cancer Panel](#)

Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

NY State Available

Yes

Specimen

Specimen Type

Varies

Ordering Guidance

Customization of this panel and single gene analysis for any gene present on this panel are available. For more

information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

Testing minors for adult-onset predisposition syndromes is discouraged by the American Academy of Pediatrics, the American College of Medical Genetics and Genomics, and the National Society of Genetic Counselors.

Shipping Instructions

Specimen preferred to arrive within 96 hours of collection.

Specimen Required

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. **Do not aliquot.**

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated

Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available:

-[Informed Consent for Genetic Testing](#) (T576)

-[Informed Consent for Genetic Testing-Spanish](#) (T826)

2. [Molecular Genetics: Inherited Cancer Syndromes Patient Information](#) (T519)

3. If not ordering electronically, complete, print, and send a [Oncology Test Request](#) (T729) with the specimen.

Specimen Minimum Volume

1 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

Clinical & Interpretive

Clinical Information

Lifetime risk for developing renal cancer in the United States is approximately 1% to 2%.⁽¹⁾ Of these cases, about 3% to 5% are associated with an underlying hereditary predisposition.^(2,3) Suspicion for a hereditary association may be raised in cases of early age of onset, multifocal/bilateral lesions, or a family or personal history of renal or other tumors.

Clear cell type renal cancers can be seen in individuals with disease-causing variants in *BAP1*, *PTEN*, and *VHL*. *BAP1* variants also associated with an increased risk for melanomas, mesothelioma, and epithelioid atypical Spitz tumors. *PTEN* variants are also associated with significantly increased risk for breast, thyroid, and uterine cancer. *VHL* variants are associated with von Hippel Lindau syndrome and are associated with an increased risk for several types of tumors, including hemangioblastomas, pancreatic cysts, neuroendocrine tumors, endolymphatic sac, and epididymal tumors.⁽⁴⁾

Risk for renal cancer is also increased by disease-causing variants in the succinate dehydrogenase-associated genes: *SDHAF2*, *SDHA*, *SDHB*, *SDHC* and *SDHD*.⁽⁵⁻⁸⁾

Variants in the *SDH* genes are also associated with an increased risk for paragangliomas and pheochromocytomas.

Hereditary papillary renal cancer may be caused by variants in the *MET* gene, while alterations in the *FH* gene cause a syndrome called hereditary leiomyomatosis and renal cell cancer (HLRCC). Individuals with HLRCC also have an increased risk of developing cutaneous or uterine leiomyomas.⁽²⁾

Birt-Hogg-Dube syndrome is caused by disease-causing variants in the *FLCN* gene. Individuals with Birt-Hogg-Dube syndrome have an increased risk for oncocytic or chromophobe renal cancers and often exhibit other features such as fibrofolliculomas, lung cysts, and pneumothorax.

Angiomyolipomas and morphologically heterogeneous renal tumors may be seen in individuals with tuberous sclerosis complex (TS), caused by variants in the *TSC1* or *TSC2* genes.⁽⁹⁾ Individuals with TS are also at increased risk for subependymal giant cell astrocytomas and may exhibit several other features, including facial angiofibromas, lymphangioleiomyomatosis, cardiac rhabdomyomas, hypomelanocytic macules, shagreen patches, and ungual/periungual fibromas.⁽¹⁰⁾

Disease-causing *DICER1* variants are associated with an increased risk of developing kidney tumors called cystic nephromas, although some individuals with *DICER1* variants have developed high-grade renal sarcomas.⁽¹¹⁾ *DICER1* tumor predisposition syndrome is also characterized by risk for pleuropulmonary blastoma, pulmonary cysts, thyroid tumors, and ovarian tumors, in addition to other features.⁽¹²⁾

A specific variant within the *MITF* gene, p.E318K, is associated with increased risk for melanoma as well as renal cancer.⁽¹³⁾

Lastly, disease-causing variants within the *SMARCA4* and *SMARCB1* genes cause a hereditary cancer syndrome called rhabdoid tumor predisposition syndrome, characterized by a significantly increased risk for aggressive, childhood-onset rhabdoid tumors, including rhabdoid tumors of the kidney.⁽¹⁴⁾

The National Comprehensive Cancer Network and the American Cancer Society provide recommendations regarding the medical management of individuals with hereditary renal cancer syndromes.⁽¹⁵⁾

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.⁽¹⁶⁾ Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Cautions

Clinical Correlations:

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data.

Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

Technical Limitations:

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

Deletion/Duplication Analysis:

This analysis targets single and multi-exon deletions/duplications; however, in some instances, single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

This test is not designed to detect low levels of mosaicism or differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

Genes may be added or removed based on updated clinical relevance. For the most up to date list of genes included in this test, detailed information regarding gene-specific performance, and technical limitations, see Method Description or [Targeted Genes and Methodology Details for the Hereditary Renal Cancer Panel](#) or contact a laboratory genetic

counselor at 800-533-1710.

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

Reclassification of Variants:

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time.

Variant Evaluation:

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.⁽¹⁶⁾ Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. Incidental findings may include, but are not limited to, results related to the sex chromosomes. These findings will be carefully reviewed to determine whether they will be reported.

Clinical Reference

1. American Cancer Society. Cancer Facts and Figures 2020. American Cancer Society; 2020. Accessed November 7, 2022. Available at www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html
2. Haas NB, Nathanson KL. Hereditary renal cancer syndromes. *Adv Chronic Kidney Dis*. 2014;21(1):81-90
3. Carlo MI, Hakimi AA, Stewart GD, Bratslavsky G, et al. Familial kidney cancer: Implications of new syndromes and molecular insights. *Eur Urol*. 2019;76(6):754-764
4. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paranglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. *Clin Cancer Res*. 2017;23(12):e68-e75
5. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. *Am J Surg Pathol*. 2014;38(12):1588-1602
6. Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. *Histopathology*. 2018;72(1):106-116
7. Lenders JW, Duh QY, Eisenhofer G, et al. Endocrine Society: Pheochromocytoma and paranglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99(6):1915-1942
8. Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paranglioma syndromes. *J Clin Endocrinol Metab*. 2006;91(3):827-836. doi:10.1210/jc.2005-1862
9. Gupta S, Jimenez RE, Herrera-Hernandez L, et al. Renal neoplasia in tuberous sclerosis: a study of 41 patients. *Mayo Clin Proc*. 2021;96(6):1470-1489
10. Henske EP, Jozwiak S, Kingswood JC, et al. Tuberous sclerosis complex. *Nat Rev Dis Primers*. 2016;2:16035

11. Doros LA, Rossi CT, Yang J, et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. *Mod Pathol*. 2014;27(9):1267-1280
12. Schultz KAP, Stewart DR, Kamihara J, et al. DICER1 tumor predisposition. In: Adam MP, Everman DB, Mirzaa GM, et al, eds: *GeneReviews* [Internet]. University of Washington, Seattle; 2014. Updated April 30, 2020. Accessed November 7, 2022. Available at www.ncbi.nlm.nih.gov/books/NBK196157/
13. Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature*. 2011;480(7375):94-98. doi:10.1038/nature10539. Erratum in: *Nature*. 2016 Mar 3;531(7592):126
14. Nemes K, Bens S, Bourdeaut F, et al. Rhabdoid tumor predisposition syndrome. In: Adam MP, Everman DB, Mirzaa GM, et al, eds: *GeneReviews* [Internet]. University of Washington, Seattle; 2017. Updated May 12, 2022 Accessed November 7, 2022. Available at www.ncbi.nlm.nih.gov/books/NBK469816/
15. Motzer RJ, Jonasch E, Boyle S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. *J Natl Compr Canc Netw*. 2020;18(9):1160-1170
16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424

Performance

Method Description

Next-generation sequencing (NGS) and/or Sanger sequencing are performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletion/insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction (PCR)-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine content, and repetitive sequences. For details regarding the targeted genes analyzed or specific gene regions not routinely covered see [Targeted Genes and Methodology Details for the Hereditary Renal Cancer Panel](#). (Unpublished Mayo method)

Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

Genes analyzed: *BAP1*, *DICER1*, *FH*, *FLCN*, *MET*, *MITF* (c.952G>A p.E318K variant only), *PTEN* (including promoter), *SDHA*, *SDHAF2*, *SDHB*, *SDHC*, *SDHD*, *SMARCA4*, *SMARCB1*, *TMEM127*, *TP53*, *TSC1*, *TSC2*, and *VHL*

PDF Report

Supplemental

Day(s) Performed

Varies

Report Available
21 to 28 days

Specimen Retention Time
Whole blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory Location
Rochester

Fees & Codes

- Fees
- Authorized users can sign in to [Test Prices](#) for detailed fee information.
 - Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
 - Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81405 x 3
81321
81406 x 2
81404 x 2
81351
81407
81479
81479 (if appropriate for government payers)

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
RENC	Hereditary Renal Cancer Panel	In Process

Result ID	Test Result Name	Result LOINC® Value
614827	Test Description	62364-5
614828	Specimen	31208-2
614829	Source	31208-2
614830	Result Summary	50397-9
614831	Result	82939-0
614832	Interpretation	69047-9
614833	Resources	99622-3

614834	Additional Information	48767-8
614835	Method	85069-3
614836	Genes Analyzed	48018-6
614837	Disclaimer	62364-5
614838	Released By	18771-6